Compare RXRX & AORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXRX | AORT |
|---|---|---|
| Founded | 2013 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 1996 |
| Metric | RXRX | AORT |
|---|---|---|
| Price | $3.50 | $28.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $7.50 | ★ $49.40 |
| AVG Volume (30 Days) | ★ 15.5M | 697.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.79 | ★ 165.62 |
| EPS | N/A | ★ N/A |
| Revenue | $74,681,000.00 | ★ $298,836,000.00 |
| Revenue This Year | $12.11 | $14.20 |
| Revenue Next Year | $82.52 | $11.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.92 | 18.01 |
| 52 Week Low | $2.77 | $19.16 |
| 52 Week High | $7.18 | $48.25 |
| Indicator | RXRX | AORT |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 57.96 |
| Support Level | $2.87 | $25.79 |
| Resistance Level | $4.03 | $38.02 |
| Average True Range (ATR) | 0.16 | 1.28 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 82.41 | 57.61 |
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.